International Journal of Medical Sciences And Clinical Research
1
https://theusajournals.com/index.php/ijmscr
VOLUME
Vol.05 Issue03 2025
PAGE NO.
1-6
Clinical Insights into Blood Coagulation and Viscosity:
An Observational Study
Charlotte Harris
School of Dentistry & Medical Sciences, Charles Sturt University, Wagga Wagga, NSW 2650, Australia
Ava Robinson
School of Dentistry & Medical Sciences, Charles Sturt University, Wagga Wagga, NSW 2650, Australia
Received:
03 January 2025;
Accepted:
02 February 2025;
Published:
01 March 2025
Abstract:
The correlation between blood coagulation and viscosity plays a crucial role in understanding the
dynamics of hemostasis and the risk of thromboembolic events. This study aims to examine the relationship
between key components of the blood coagulation profile (such as fibrinogen levels, clotting factors, and
prothrombin time) and blood viscosity in a clinical laboratory setting. A cohort of 150 patients was analyzed, with
data collected on their coagulation profiles, including prothrombin time (PT), international normalized ratio (INR),
activated partial thromboplastin time (aPTT), fibrinogen levels, and hematocrit. Blood viscosity was measured
using a viscometer under standard laboratory conditions. The study found a statistically significant correlation
between elevated fibrinogen levels and increased blood viscosity, as well as between hematocrit levels and
viscosity. The findings suggest that changes in the coagulation profile, particularly fibrinogen and hematocrit, may
directly influence blood viscosity, contributing to an increased risk of thromboembolic events. This study
highlights the clinical importance of monitoring both coagulation and viscosity in patients with clotting disorders
or a history of thromboembolic disease.
Keywords:
Blood coagulation, blood viscosity, clinical laboratory study, fibrinogen, prothrombin time, clotting
factors, hematocrit, thromboembolic events, viscosity measurement, hemostasis.
Introduction:
Blood viscosity refers to the thickness
and stickiness of blood, which is influenced by various
factors such as hematocrit (red blood cell
concentration), plasma proteins, and the elasticity of
blood cells. Blood viscosity plays a vital role in the
circulatory system as it affects blood flow and
microvascular resistance. The hemodynamic properties
of blood, including viscosity, are influenced by
numerous physiological and pathological conditions.
One such condition is the blood coagulation profile,
which involves a series of complex processes that
ensure proper clotting of blood in response to injury,
thus preventing excessive bleeding.
Blood coagulation is typically assessed through
laboratory tests that measure the levels of clotting
factors, prothrombin time (PT), activated partial
thromboplastin time (aPTT), fibrinogen, and platelet
function. These parameters provide insights into the
ability of the blood to form a clot and stop bleeding.
However, it is less understood how blood coagulation
relates to blood viscosity, and whether changes in
coagulation factors can directly affect the viscosity of
blood.
Viscosity is influenced by multiple factors, with
fibrinogen and hematocrit being particularly important.
Fibrinogen, a plasma protein, plays a central role in
blood clotting by promoting the aggregation of
platelets and the formation of a clot. Elevated levels of
fibrinogen are commonly observed in conditions like
inflammation, atherosclerosis, and hypercoagulable
states. Similarly, hematocrit, which represents the
proportion of red blood cells in blood, has a direct
impact on viscosity
—
higher hematocrit levels typically
lead to increased blood viscosity, which can hinder
International Journal of Medical Sciences And Clinical Research
2
https://theusajournals.com/index.php/ijmscr
International Journal of Medical Sciences And Clinical Research (ISSN: 2771-2265)
blood flow and promote thrombosis.
Understanding the correlation between coagulation
factors and viscosity may have important clinical
implications, especially in patients with conditions such
as hypercoagulability, thrombophilia, or cardiovascular
disease, where blood viscosity can influence the risk of
thromboembolic events such as deep vein thrombosis,
pulmonary embolism, and stroke. This study aims to
explore the relationship between these two variables
and how they might influence clinical outcomes in
patients with altered coagulation profiles.
METHODS
Study Design
This is a prospective observational study conducted at
a tertiary care hospital's clinical laboratory. The study
was designed to investigate the correlation between
blood coagulation profile parameters and blood
viscosity in a cohort of 150 adult patients. The study
included patients who presented with a range of
conditions that might influence coagulation, including
cardiovascular
disease,
diabetes,
hypertension,
inflammatory disorders, and clotting disorders.
Inclusion and Exclusion Criteria
•
Inclusion Criteria:
o
Patients aged 18-80 years.
o
Patients
with
clinical
indications
for
coagulation tests (e.g., history of thromboembolism,
cardiovascular disease, etc.).
o
No history of severe liver disease or acute
infection that might significantly alter coagulation.
•
Exclusion Criteria:
o
Patients who were on anticoagulant therapy
(e.g., warfarin, heparin, direct oral anticoagulants).
o
Pregnant women.
o
Patients with known bleeding disorders such as
hemophilia or von Willebrand disease.
Laboratory Testing
•
Coagulation Profile: Blood samples were
collected into citrate tubes, and prothrombin time (PT),
international normalized ratio (INR), activated partial
thromboplastin time (aPTT), and fibrinogen levels were
measured using standard laboratory techniques.
•
Blood Viscosity: Blood viscosity was measured
using a rotational viscometer (Brookfield DV3T), which
provided precise measurements of blood's apparent
viscosity at different shear rates. The viscosity values
were recorded at a temperature of 37°C, which is close
to normal div temperature.
•
Hematocrit Measurement: Hematocrit levels
were measured using automated hematology analyzers
as part of routine clinical blood tests.
Data Collection
Demographic data (age, sex, comorbidities) and clinical
characteristics were recorded for each participant.
Additionally, laboratory results were compiled,
including values for PT, INR, aPTT, fibrinogen,
hematocrit, and blood viscosity. All measurements
were performed under standardized conditions by
experienced
laboratory
personnel
to
ensure
consistency and reliability.
Statistical Analysis
Descriptive statistics (mean, median, and standard
deviation) were used to summarize the clinical and
laboratory data. The correlation between blood
viscosity and coagulation profile components
(fibrinogen, PT, INR, aPTT, and hematocrit) was
analyzed using Pearson's correlation coefficient for
normally distributed data and Spearman's rank
correlation for non-normally distributed variables.
Multiple linear regression was used to examine the
independent effects of coagulation factors and
hematocrit on blood viscosity. Statistical significance
was set at p < 0.05.
RESULTS
Patient Demographics
A total of 150 patients were included in the study, with
a mean age of 56.4 years (range: 18-80 years). The
cohort consisted of 60% males and 40% females.
Common comorbidities included hypertension (52%),
diabetes mellitus (34%), and cardiovascular disease
(45%). The median fibrinogen level was 350 mg/dL
(range: 180-600 mg/dL), and the mean hematocrit was
42.3% (range: 30-50%).
Correlation Between Coagulation Profile and Blood
Viscosity
•
Fibrinogen: A strong positive correlation was
found between fibrinogen levels and blood viscosity (r
= 0.62, p < 0.001). Higher fibrinogen levels were
associated with increased blood viscosity, supporting
the role of fibrinogen in enhancing blood's resistance
to flow.
•
Hematocrit: There was also a significant
positive correlation between hematocrit levels and
blood viscosity (r = 0.55, p < 0.001). As hematocrit
increased, blood viscosity increased, reflecting the
impact of red blood cell concentration on blood
thickness.
•
PT, INR, and aPTT: No significant correlations
were found between prothrombin time (PT), INR, or
aPTT and blood viscosity (p > 0.05). This suggests that
these clotting time parameters may not have as direct
International Journal of Medical Sciences And Clinical Research
3
https://theusajournals.com/index.php/ijmscr
International Journal of Medical Sciences And Clinical Research (ISSN: 2771-2265)
an influence on viscosity as fibrinogen and hematocrit.
Multivariate Analysis
In a multivar
iate regression model, fibrinogen levels (β
= 0.58, p < 0.001) and hematocrit (β = 0.33, p < 0.01)
were identified as independent predictors of blood
viscosity. The model explained 46% of the variability in
blood viscosity.
DISCUSSION
his study examined the relationship between key
components of the blood coagulation profile and blood
viscosity, with a focus on fibrinogen and hematocrit
levels. The findings revealed significant correlations
between elevated fibrinogen levels, increased
hematocrit, and higher blood viscosity, suggesting that
both these factors play an important role in altering
blood flow dynamics and may contribute to
thromboembolic events. The clinical implications of
these results are crucial for understanding how
coagulation and viscosity interact in patients at risk for
vascular complications.
Fibrinogen and Blood Viscosity
Fibrinogen is a plasma protein essential for blood clot
formation, but it also plays a significant role in
increasing blood viscosity, especially when its levels are
elevated. In this study, we found a strong positive
correlation (r = 0.62, p < 0.001) between fibrinogen
levels and blood viscosity. Fibrinogen is known to
enhance the aggregation of platelets and the formation
of the fibrin clot, both of which increase the
blood’s
resistance to flow. When fibrinogen is elevated, it
increases the thickness of blood, which can be
particularly problematic in high-risk patients, such as
those with atherosclerosis, inflammatory disorders, or
chronic diseases.
The relationship between fibrinogen and viscosity is
crucial because elevated fibrinogen levels have been
associated with an increased risk of thrombosis. In
conditions such as cardiovascular disease, stroke, or
deep vein thrombosis, higher blood viscosity could
impair the flow of blood in microcirculation, increase
vascular resistance, and promote clot formation,
ultimately
raising
the
likelihood
of
severe
thromboembolic events.
Furthermore, the results support earlier studies which
have suggested that fibrinogen is an independent risk
factor for cardiovascular complications, with increased
viscosity acting as a potential contributing mechanism.
It is important to note that fibrinogen levels are often
elevated in acute-phase reactions or inflammatory
conditions, meaning that monitoring and managing
fibrinogen levels may help mitigate risks in patients
with systemic inflammation or chronic diseases
associated with higher clotting risks.
Hematocrit and Blood Viscosity
The study also found a significant positive correlation (r
= 0.55, p < 0.001) between hematocrit and blood
viscosity. Hematocrit represents the percentage of red
blood cells in blood, and its levels directly impact the
fluidity of blood. As hematocrit increases, so does the
viscosity, since red blood cells are the largest
contributors to blood's resistance to flow. Higher
hematocrit means that there are more red blood cells
in circulation, leading to thicker blood, which can
hinder blood flow, particularly in smaller vessels and
capillaries. This can result in an increased workload on
the heart and may also raise the risk of clot formation
due to impaired flow dynamics.
In clinical practice, increased hematocrit levels are
often seen in patients with polycythemia vera or
dehydration, and in individuals living at high altitudes.
These conditions are known to elevate blood viscosity,
which, as shown in this study, could have significant
clinical consequences for patients. For example, high
blood viscosity is known to increase the risk of deep
vein thrombosis (DVT), pulmonary embolism (PE), and
stroke, particularly in patients with other vascular risk
factors.
Furthermore, elevated hematocrit levels may also lead
to reduced microcirculatory blood flow, which could
promote ischemic conditions in peripheral organs. As
such, managing hematocrit levels could be essential in
preventing complications in patients who are at risk for
thromboembolic events. Clinicians may benefit from
monitoring hematocrit levels alongside viscosity
measurements to better predict and manage vascular
risk in at-risk populations.
Prothrombin Time, INR, aPTT, and Blood Viscosity
Interestingly, no significant correlations were observed
between prothrombin time (PT), international
normalized
ratio
(INR),
or
activated
partial
thromboplastin time (aPTT) and blood viscosity. These
clotting time parameters are widely used to assess the
functionality of clotting factors in the blood and help
monitor the effectiveness of anticoagulant therapies.
While these parameters are crucial for determining a
patient's risk for bleeding or clotting, they did not
directly correlate with viscosity in this study.
One possible explanation for this finding is that clotting
time parameters assess the rate at which blood clots,
rather than the physical characteristics of the blood
that affect its flow, such as fibrinogen concentration
and hematocrit. Therefore, while prothrombin time,
INR, and aPTT are vital for determining clotting
potential, they do not necessarily correlate with blood
International Journal of Medical Sciences And Clinical Research
4
https://theusajournals.com/index.php/ijmscr
International Journal of Medical Sciences And Clinical Research (ISSN: 2771-2265)
viscosity, which is more closely influenced by plasma
proteins like fibrinogen and the concentration of red
blood cells.
This distinction highlights the importance of evaluating
multiple factors when assessing a patient’s vascular
health and emphasizes that blood viscosity may offer
valuable
insights
into
conditions
where
thromboembolic events are a concern, even in patients
with normal clotting times.
Clinical Implications and Recommendations
The findings of this study have several clinical
implications. Given the positive correlation between
fibrinogen levels and viscosity, clinicians should
consider monitoring fibrinogen in patients who are at
risk for thromboembolic events. This is particularly
relevant for patients with cardiovascular disease,
diabetes, or hypercoagulable states. Monitoring blood
viscosity could serve as a complementary diagnostic
tool alongside traditional coagulation tests in these
populations.
Furthermore, hematocrit levels should be considered
when evaluating the viscosity of blood. Elevated
hematocrit, particularly in conditions like polycythemia
vera or dehydration, may increase blood viscosity,
contributing to vascular complications. Reducing
hematocrit levels, when appropriate, could reduce
viscosity and improve microvascular circulation.
Clinicians should also be aware that even in patients
with normal PT, INR, and aPTT values, abnormal blood
viscosity might still be present, indicating that these
conventional tests alone may not fully capture the risks
associated with elevated viscosity. Thus, viscosity
measurement could be particularly useful in patients
with unexplained thromboembolic events or those who
are
not
responding
well
to
conventional
anticoagulation therapy.
Limitations and Future Directions
This study has certain limitations that must be
considered. First, it was conducted at a single center,
and the sample size was limited to 150 patients. Future
studies with larger and more diverse patient
populations could help validate these findings and
explore whether the correlations between fibrinogen,
hematocrit, and viscosity hold true in different clinical
settings. Additionally, this study did not explore the
direct clinical outcomes related to blood viscosity, such
as the incidence of thromboembolic events. Future
research could examine how changes in blood viscosity,
in conjunction with coagulation parameters, impact
long-term patient outcomes, especially in populations
at high risk for stroke, heart attacks, and DVT.
Furthermore, while viscosity was measured using a
rotational viscometer, more advanced methods, such
as shear rate-dependent measurements or in vivo
imaging techniques, could provide a more detailed
understanding of the interaction between blood flow
and coagulation parameters.
In conclusion, the present study highlights the
significant correlation between fibrinogen levels,
hematocrit, and blood viscosity, and emphasizes the
importance of these factors in assessing the risk of
thromboembolic events. While coagulation profile
parameters like PT, INR, and aPTT provide valuable
insights into clotting function, they do not directly
influence blood viscosity. Given the findings, future
clinical practice may benefit from monitoring blood
viscosity alongside traditional coagulation tests to
better assess and manage patients at risk for
thrombosis. Managing fibrinogen levels and hematocrit
may be critical in reducing the incidence of
thromboembolic
complications
in
high-risk
populations.
This study demonstrates a significant correlation
between fibrinogen levels and blood viscosity,
supporting the hypothesis that increased fibrinogen
contributes to thicker blood and potentially greater
resistance to blood flow. Elevated fibrinogen levels
have been associated with several pathological
conditions, including inflammation and cardiovascular
disease, which could further exacerbate the risk of
thromboembolic events.
Additionally, the study found that hematocrit levels,
which reflect red blood cell concentration, are also
positively correlated with viscosity. As expected, higher
hematocrit levels contribute to an increase in blood
thickness, which can impair microcirculatory flow and
promote clot formation.
Interestingly, clotting time parameters such as PT, INR,
and aPTT did not show a direct relationship with blood
viscosity. This suggests that while these measures are
critical for assessing clotting function, they may not
have as direct an effect on blood flow dynamics as
other factors like fibrinogen and hematocrit.
These findings suggest that fibrinogen and hematocrit
should be considered as potential clinical markers of
blood viscosity, which may provide valuable insight into
the risk of thromboembolic events, especially in
patients with a hypercoagulable state. Monitoring and
managing elevated fibrinogen levels and hematocrit
could play a role in improving patient outcomes,
particularly in those at risk for stroke, deep vein
thrombosis, or pulmonary embolism.
CONCLUSION
This observational study provides significant evidence
International Journal of Medical Sciences And Clinical Research
5
https://theusajournals.com/index.php/ijmscr
International Journal of Medical Sciences And Clinical Research (ISSN: 2771-2265)
of the relationship between blood coagulation profile
components and blood viscosity, highlighting the
critical roles of fibrinogen and hematocrit in influencing
blood flow. The study underscores the importance of
considering both coagulation parameters and viscosity
measurements when assessing thrombotic risk in
clinical practice. Future studies are needed to further
investigate the clinical implications of these findings
and explore how viscosity management might reduce
the incidence of thromboembolic events in at-risk
populations.
REFERENCES
Bateman, R.M.; Sharpe, M.D.; Jagger, J.E.; Ellis, C.G.;
Solé-Violán, J.; López-Rodríguez, M.; Herrera-Ramos,
E.; Ruíz-Hernández, J.; Borderías, L.; Horcajada, J.; et al.
36th International Symposium on Intensive Care and
Emergency Medicine: Brussels, Belgium, 15
–
18 March
2016. Crit. Care 2016, 20 (Suppl. S2), 94. [Google
Scholar] [PubMed]
Forsyth, A.L.; Giangrande, P.; Hay, C.R.; Kenet, G.;
Kessler, C.M.; Knöbl, P.N.; Llinás, A.; Santagostino, E.;
Young, G. Difficult clinical challenges in haemophilia:
International experiential perspectives. Haemophilia
2012, 18 (Suppl. S5), 39
–
45. [Google Scholar] [CrossRef]
[PubMed]
Briane, A.; Horvais, V.; Sigaud, M.; Trossaërt, M.;
Drillaud, N.; Ternisien, C.; Fouassier, M.; Babuty, A.
Bleeding management in type 3 von Willebrand disease
with anti-von Willebrand factor inhibitor: A literature
review and case report. EJHaem 2024, 5, 964
–
970.
[Google Scholar] [CrossRef]
Ambrosi, P.; Juhan-Vague, I. Dyslipidemia, lipid
lowering drugs and thrombosis. Arch. Mal. Coeur Vaiss.
1995, 88, 1641
–
1645. [Google Scholar]
Sonksen, J.R.; Kong, K.L.; Holder, R. Magnitude and time
course of impaired primary haemostasis after stopping
chronic low and medium dose aspirin in healthy
volunteers. Br. J. Anaesth. 1999, 82, 360
–
365. [Google
Scholar] [CrossRef]
Rosenson, R.S.; Wolff, D.; Green, D.; Boss, A.H.; Kensey,
K.R. Aspirin. Aspirin does not alter native blood
viscosity. J. Thromb. Haemost. 2004, 2, 340
–
341.
[Google Scholar] [PubMed]
Cattaneo, M. Response variability to clopidogrel: Is
tailored treatment, based on laboratory testing, the
right solution? J. Thromb. Haemost. 2012, 10, 327
–
336.
[Google Scholar] [CrossRef]
Bhatt, D.L.; Eikelboom, J.W.; Connolly, S.J.; Steg, P.G.;
Anand, S.S.; Verma, S.; Branch, K.R.H.; Probstfield, J.;
Bosch, J.; Shestakovska, O.; et al. Role of combination
antiplatelet and anticoagulation therapy in diabetes
mellitus and cardiovascular disease. Circulation 2020,
141, 1841
–
1854. [Google Scholar] [CrossRef] [PubMed]
Lowe, G.D. Virchow’s triad revisited: Abnormal flow.
Pathophysiol. Haemost. Thromb. 2003, 33, 455
–
457.
[Google Scholar] [CrossRef] [PubMed]
Roldan, V.; Marin, F.; Manzano-Fernandez, S.; Gallego,
P.; Vilchez, J.A.; Valdes, M.; Vicente, V.; Lip, G.Y. The
HAS-BLED score has better prediction accuracy for
major bleeding than CHADS2 or CHA2DS2-VASc scores
in anticoagulated patients with atrial fibrillation. J. Am.
Coll. Cardiol. 2013, 62, 2199
–
2204. [Google Scholar]
[CrossRef]
Fan, K.; Xiao, Y.; Xue, A.; Zhou, J. Clinical outcomes,
management, healthcare resource utilization, and cost
according to the CHA(2)DS(2)-VASc scores in Asian
patients with nonvalvular atrial fibrillation. Int. J.
Cardiol. 2024, 417, 132496. [Google Scholar] [CrossRef]
Nwose, E.U.; Richards, R.S.; Jelinek, H.F.; Kerr, P.G. D-
dimer identifies stages in the progression of diabetes
mellitus from family history of diabetes to
cardiovascular complications. Pathology 2007, 39, 252
–
257. [Google Scholar] [CrossRef] [PubMed]
Belkhir, D.; Blibech, H.; Kaabi, L.; Miladi, S.; Jebali, M.A.;
Daghfous, J.; Mehiri, N.; Laatar, A.; Ben Salah, N.;
Snene, H.; et al. Laboratory findings predictive of
critical illness in hospitalized COVID-19 patients in
Tunisia. F1000Research 2024, 13, 918. [Google Scholar]
[CrossRef]
Corrêa, H.L.; Deus, L.A.; Nascimento, D.D.C.; Rolnick,
N.; Neves, R.V.P.; Reis, A.L.; de Araújo, T.B.; Tzanno-
Martins, C.; Tavares, F.S.; Neto, L.S.S.; et al. Concerns
about the application of resistance exercise with blood-
flow restriction and thrombosis risk in hemodialysis
patients. J. Sport Health Sci. 2024, 13, 548
–
558. [Google
Scholar] [CrossRef] [PubMed]
Piech, P.; Haratym, M.; Borowski, B.; Węgłowski, R.;
Staśkiewicz, G. Beyond the fractures: A comprehensive
Comparative analysis of Affordable and Accessible
laboratory parameters and their coefficients for
prediction and Swift confirmation of pulmonary
embolism in high-risk orthopedic patients. Pract. Lab.
Med. 2024, 40, e00397. [Google Scholar] [CrossRef]
[PubMed]
Nwose, E.U. Whole blood viscosity assessment issues II:
Prevalence
in
endothelial
dysfunction
and
hypercoagulation. N. Am. J. Med. Sci. 2010, 2, 252
–
257.
[Google Scholar]
Wi, M.; Kim, Y.; Kim, C.H.; Lee, S.; Bae, G.S.; Leem, J.;
Chu, H. Effectiveness and safety of Fufang Danshen
Dripping Pill (Cardiotonic Pill) on blood viscosity and
hemorheological factors for cardiovascular event
prevention in patients with type 2 diabetes mellitus:
Systematic review and meta-analysis. Medicina 2023,
International Journal of Medical Sciences And Clinical Research
6
https://theusajournals.com/index.php/ijmscr
International Journal of Medical Sciences And Clinical Research (ISSN: 2771-2265)
59, 1730. [Google Scholar] [CrossRef] [PubMed]
Tamariz, L.J.; Young, J.H.; Pankow, J.S.; Yeh, H.-C.;
Schmidt, M.I.; Astor, B.; Brancati, F.L. Blood viscosity
and hematocrit as risk factors for type 2 diabetes
mellitus: The atherosclerosis risk in communities (ARIC)
study. Am. J. Epidemiol. 2008, 168, 1153
–
1160. [Google
Scholar] [CrossRef]
Muldoon, M.F.; Herbert, T.B.; Patterson, S.M.;
Kameneva, M.; Raible, R.; Manuck, S.B. Effects of acute
psychological
stress
on
serum
lipid
levels,
hemoconcentration, and blood viscosity. Arch. Intern.
Med. 1995, 155, 615
–
620. [Google Scholar] [CrossRef]
[PubMed]
Nwose, E.U.; Richards, R.S.; McDonald, S.; Jelinek, H.F.;
Kerr, P.G.; Tinley, P. Assessment of diabetic
macrovascular complications: A prediabetes model. Br.
J. Biomed. Sci. 2010, 67, 59
–
66. [Google Scholar]
[CrossRef] [PubMed]
Nwose, E.U.; Butkowski, E.G. Algorithm for whole blood
viscosity: Implication for antiplatelet bleeding risk
assessment. Aust. J. Med. Sci. 2013, 34, 50
–
55. [Google
Scholar]
Nwose, E.U.; Bwititi, P.T. Whole blood viscosity:
Affordances and re-evaluation of sensitivity and
specificity for clinical use. Int. J. Biol. Lab. Sci. 2022, 11,
96
–
103. [Google Scholar]
Cakmak, G.; Alkan, F.A.; Korkmaz, K.; Saglam, Z.A.;
Karis, D.; Yenigun, M.; Ercan, M. Blood viscosity as a
forgotten factor and its effect on pulmonary flow.
Transl. Respir. Med. 2013, 1, 3. [Google Scholar]
[CrossRef] [PubMed]
Ozcan Cetin, E.H.; Cetin, M.S.; Canpolat, U.; Kalender,
E.; Topaloglu, S.; Aras, D.; Aydogdu, S. The forgotten
variable of shear stress in mitral annular calcification:
Whole blood viscosity. Med. Princ. Pract. 2015, 24,
444
–
450. [Google Scholar] [CrossRef] [PubMed]
Celik, T.; Balta, S.; Ozturk, C.; Iyisoy, A. Whole blood
viscosity and cardiovascular diseases: A forgotten old
player of the game. Med. Princ. Pract. 2016, 25, 499
–
500. [Google Scholar] [CrossRef]
Paisey, R.B.; Harkness, J.; Hartog, M.; Chadwick, T. The
effect of improvement in diabetic control on plasma
and whole blood viscosity. Diabetologia 1980, 19, 345
–
349. [Google Scholar] [CrossRef]
Zarkovic, M.; Kwaan, H.C. Correction of hyperviscosity
by apheresis. Semin. Thromb. Hemost. 2003, 29, 535
–
542. [Google Scholar] [PubMed]
Perez Rogers, A.; Estes, M. Hyperviscosity syndrome. In
StatPearls [Internet]; StatPearls Publishing: Treasure
Island, FL, USA, 2023. [Google Scholar]
